869478-12-6

Basic information

• Product Name: (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one
• Synonyms: (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one;8-(2R)-Oxiranyl-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one;6-benzyloxy-(8R)-oxiranyl-4H-benzo[1,4]oxazin-3-one
• CAS NO: 869478-12-6
• Molecular Formula: C₁₇H₁₅NO₄
• Molecular Weight: 297.3053
• EINECS: 925-223-9
• Mol File: 869478-12-6.mol

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one(869478-12-6)
• EPA Substance Registry System: (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one(869478-12-6)

Safety Data

• Hazardous Substances Data: 869478-12-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one is used as a key intermediate in the synthesis of Olodaterol (O262000), a novel inhaled β2-adrenoceptor agonist. (R)-6-Benzyloxy-8-(oxiran-2-yl)-4H-benzo[1,4]oxazin-3-one is specifically utilized for its role in creating a medication with a 24-hour bronchodilatory efficacy, which is beneficial for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Upstream product

• 869478-09-1 8-acetyl-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one 
• 861841-90-9 1-[2-hydroxy-3-amino-5-(benzyloxy)phenyl]ethanone 
• 861841-94-3 1‐[2-hydroxy-3-nitro-5-(benzyloxy)phenyl]ethanone 
• 30992-63-3 5-benzyloxy-2-hydroxyacetophenone 
• 490-78-8 2,5-Dihydroxyacetophenone 
• 926319-53-1 8-(bromoacetyl)-6-(phenylmethoxy)-2H-1,4-benzoxazin-3(4H)-one 
• 869478-11-5 6-benzyloxy-8-((R)-2-chloro-1-hydroxyethyl)-4H-benzo[1,4]-oxazin-3-one 

Downstream Products

• 869478-13-7 6-benzyloxy-8-{(R)-1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]ethyl}-4H-benzo[1,4]oxazin-3-one 
• 926319-48-4 6-(phenylmethoxy)-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride 
• 950202-93-4 6-benzyloxy-8-{(R)-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-benzimidazol-1-yl)-1,1-dimethyl-butylamino]-1-hydroxy-ethyl}-4H-benzo[1,4]oxazin-3-one 
• 926692-03-7 C₂₇H₂₈F₂N₂O₄ 

Relevant articles and documents

Preparation method of olodaterol and salts thereof

The invention relates to a preparation method of olodaterol and salts thereof, which comprises the following steps: in a solvent, carrying out oxidation and nucleophilic addition reaction on a compound shown in a formula I to obtain a compound shown in a

Crystal form C of olodaterol hydrochloride and preparation method thereof

The invention relates to a crystal form C of a long-acting beta2 adrenergic agonist olodaterol hydrochloride and a preparation method thereof and a pharmaceutical composition containing the crystal form C. The crystal form is represented by the characteri

Olodaterol hydrochloride crystal form A and preparation method thereof

The invention relates to a long-acting beta 2 adrenergic agonist drug olodaterol hydrochloride crystal form A, a preparation method thereof and and a pharmaceutical composition containing the crystalform A. The crystal form is characterized by X-ray diffr

Hydrochloric acid [...] B and its preparation method

The invention relates to a long-acting β2 Adrenal can agonist pharmaceutical hydrochloride crystalline form of [...] B and its preparation method, B and containing said form of the pharmaceutical composition, this crystalline form to its X-ray

Benzoxazine compound and its preparation methods and application

The invention relates to a benzoxazine compound represented in the following formula 1. The benzoxazine compound can serve as a beta 2 receptor agonist. The formula can be seen from the description.

PROCESS FOR THE MANUFACTURING OF BETA MIMETICS

The invention relates to a method for producing betamimetics of formula (1), wherein in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 represents hydrogen, halogen, C

Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy

Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity. A complete reversal of acetylcholine-induced bronchoconstrictio

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

The present invention relates to enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3, R4 and X? may have the meanings given in the claims and in the specification, proce

NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG

The invention relates to enantiomerically pure compounds of formula (1), wherein the radicals R1, R2, R3, R4and X are defined as in claims and a description. A method for producing said compounds and the use thereof